At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Necitumumabbiological
Likely dose
Necitumumab 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Necitumumab for Solid Tumors. Completed, enrolled 75 participants across 8 sites.
Detailed Summary
The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard treatment is available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartAug 2012
Primary CompletionMay 2014
Study CompletionJun 2015
TodayJul 2026
First PostedJun 20, 2012
Enrollment StartAug 1, 2012
Primary CompletionMay 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.0 years ago
Interventions
Necitumumabbiological
800 mg necitumumab, administered once per week IV